T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$4.45B |
| 2 |
JPMorgan Chase
JPM
|
+$2.22B |
| 3 |
Atlassian
TEAM
|
+$2.08B |
| 4 |
NVIDIA
NVDA
|
+$1.81B |
| 5 |
Apple
AAPL
|
+$1.67B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$3.24B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.08B |
| 3 |
Microsoft
MSFT
|
+$2.68B |
| 4 |
Wells Fargo
WFC
|
+$1.93B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.86B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.79% |
| 2 | Healthcare | 17.2% |
| 3 | Consumer Discretionary | 15.17% |
| 4 | Financials | 10.75% |
| 5 | Communication Services | 10.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1476
Old Republic International
ORI
$10.3B
| $4.49M | ﹤0.01% |
173,440
+29,626
| +21% | +$764K |
|
1477
Tenaris
TS
$26.8B
| $4.48M | ﹤0.01% |
148,900
+79,200
| +114% | +$2.06M |
|
1478
Zillow
Z
$7.82B
| $4.47M | ﹤0.01% |
90,767
-330
| -0.4% | -$17.7K |
|
1479
Under Armour
UAA
$2.29B
| $4.43M | ﹤0.01% |
260,588
-1,164
| -0.4% | -$20.9K |
|
1480
Madrigal Pharmaceuticals
MDGL
$11.6B
| $4.41M | ﹤0.01% |
44,899
-3,554
| -7% | -$300K |
|
1481
Murphy Oil
MUR
$4.97B
| $4.37M | ﹤0.01% |
108,235
-23,490
| -18% | -$805K |
|
1482
Oshkosh
OSK
$9.44B
| $4.34M | ﹤0.01% |
43,137
+1,984
| +5% | +$223K |
|
1483
Aecom
ACM
$8.04B
| $4.33M | ﹤0.01% |
56,367
+4,409
| +8% | +$324K |
|
1484
Axalta
AXTA
$7.97B
| $4.32M | ﹤0.01% |
175,583
+5,845
| +3% | +$163K |
|
1485
Relmada Therapeutics
RLMD
$508M
| $4.25M | ﹤0.01% |
+157,565
| New | +$3.26M |
|
1486
Jazz Pharmaceuticals
JAZZ
$15.8B
| $4.1M | ﹤0.01% |
26,366
+2,563
| +11% | +$372K |
|
1487
Helmerich & Payne
HP
$4.35B
| $4.06M | ﹤0.01% |
94,975
+8,493
| +10% | +$293K |
|
|
COHR
1488
DELISTED
Coherent Inc
COHR
| $4.06M | ﹤0.01% |
14,861
-1,899
| -11% | -$497K |
|
1489
ManpowerGroup
MAN
$2.73B
| $4.05M | ﹤0.01% |
43,174
+4,159
| +11% | +$424K |
|
1490
Seres Therapeutics
MCRB
$46.9M
| $4.05M | ﹤0.01% |
28,410
+382
| +1% | +$58.8K |
|
1491
Recursion Pharmaceuticals
RXRX
$1.72B
| $4.03M | ﹤0.01% |
562,190
-295,383
| -34% | -$3.14M |
|
1492
First Citizens BancShares
FCNCA
$25.7B
| $3.98M | ﹤0.01% |
5,981
+2,456
| +70% | +$1.91M |
|
|
GMS
1493
DELISTED
GMS Inc
GMS
| $3.96M | ﹤0.01% |
79,495
+865
| +1% | +$45.5K |
|
1494
Upstart Holdings
UPST
$2.97B
| $3.95M | ﹤0.01% |
36,244
+8,607
| +31% | +$992K |
|
1495
Reinsurance Group of America
RGA
$16.3B
| $3.94M | ﹤0.01% |
36,038
+2,285
| +7% | +$253K |
|
1496
Hancock Whitney
HWC
$6.37B
| $3.9M | ﹤0.01% |
74,737
+17,467
| +30% | +$942K |
|
|
MPT
1497
Medical Properties Trust
MPT
$2.52B
| $3.87M | ﹤0.01% |
182,820
+16,131
| +10% | +$348K |
|
|
TEAD
1498
Teads Holding Co
TEAD
$65.7M
| $3.85M | ﹤0.01% |
+359,168
| New | +$4.51M |
|
1499
Lear
LEA
$8.21B
| $3.85M | ﹤0.01% |
26,963
-1,015
| -4% | -$165K |
|
|
ALLK
1500
DELISTED
Allakos
ALLK
| $3.84M | ﹤0.01% |
673,736
+431,599
| +178% | +$2.79M |
|
Similar funds
T. Rowe Price Associates's Q1 2022 Portfolio in Review
As of Q1 2022, T. Rowe Price Associates held 3,085 positions worth $992B, down 11% from $1.11T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q1 2022 filing shows 108 new, 1,637 increased, 1,059 reduced and 107 closed positions. Its largest new stake was Nutrien: 6,143,560 shares worth $639M. The largest sale was Alphabet (Google) Class C, an estimated $3.24B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2022 buy was Nutrien: 6,143,560 shares worth $639M.
- T. Rowe Price Associates added most to Tesla in Q1 2022, an estimated $4.45B increase.
- T. Rowe Price Associates's biggest Q1 2022 reduction was Alphabet (Google) Class C, cutting an estimated $3.24B.
- T. Rowe Price Associates fully exited Xilinx Inc in Q1 2022, selling an estimated $481M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $992B portfolio in Q1 2022.
- T. Rowe Price Associates opened 108 new positions and closed 107 in Q1 2022.
- T. Rowe Price Associates's portfolio value fell 11% quarter-over-quarter to $992B.
Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.